Buzzing on Yahoo Sports:

Cagewriter

UFC's Dan Henderson unsure of future without TRT

Cagewriter
MMA: UFC 161-Evans vs Henderson
.

View photo

Hendo gonna Hendo. (Tom Szczerbowski-USA TODAY Sports)

Dan Henderson has been granted one more therapeutic use exemption (TUE) for testosterone replacement therapy (TRT) for his fight this Saturday against Mauricio "Shogun" Rua, and isn't all too happy about the prospect of doing without the treatment. The 43 year-old says that the recent banning of TRT by athletic commissions will do nothing to solve illicit performance-enhancing drug use among fighters.

Like Georges St. Pierre, Henderson believes that a more effective strategy would be to increase and randomize testing of athletes.

"The biggest issue is that it didn't solve any problems by taking it away. It doesn't really address the real issue of tackling the problem of performance enhancing drugs," Henderson told Damon Martin.

"I think if they really wanted to make a statement they should have done more drug testing and implemented no advance notice in drug testing. Show up at guys' houses at odd hours and make them give blood and pee in a cup."

Henderson recently signed a new six-fight deal with the UFC but isn't thinking beyond the fight with Rua. One reason is to focus on the challenge at hand and the other is because the former Olympic wrestler will need to determine if and how he can continue competing without TRT.

"I'm pretty much going to get this fight handled and worry about the changes later," Henderson explained.

"I don't need to make any decisions now. I'm going to have to do some research and see what's out there. "I'm sure my levels were low before I started taking [TRT] for years and I got by just fine. It's just unfortunate that a doctor's prescription for something that would make me healthier can't be used in this situation. Like I said, the biggest issue is they need to do some better drug testing."

Follow Elias on Twitter @EliasCepeda & @YahooCagewriter

Sign up for Yahoo Fantasy Football
View Comments (35)